Literature DB >> 2903210

In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A.

A Granelli-Piperno1.   

Abstract

RNA-RNA in situ hybridization was used to study the frequency of cells producing mRNA for IL-2 and IL-2-R in T lymphocytes stimulated by either of three mitogens: anti-CD3, anti-CD28, or PHA. Both CD4+ and CD8+ T cells expressed transcripts for IL-2 and the low-affinity IL-2-R when stimulated with these mitogens plus PMA. IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3. However, higher concentrations of CSA were necessary to achieve 50-70% inhibition after stimulation with anti-CD28. At optimal points 12-22% of CD4+ and 5-13% of CD8+ cells expressed IL-2 mRNA, while 30-50% of cells of both subsets had IL-2-R mRNA. The IL-2 grain counts, which relate to the level of mRNA/cell, were higher in the CD4+ subset but could be increased several fold in the CD8+ subset in the presence of adherent accessory cells. The use of PMA as an accessory stimulus, in addition to adherent cells, greatly increased the frequency of lymphocytes with IL-2 mRNA and the amount of IL-2 activity in the culture medium, but the proliferative response was not significantly boosted. These observations indicate at the single cell level that many CD4+ or CD8+ lymphocytes can make IL-2 mRNA, and that the induction of IL-2 with several stimuli is reduced by CSA and enhanced by PMA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903210      PMCID: PMC2189101          DOI: 10.1084/jem.168.5.1649

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.

Authors:  A Aruffo; B Seed
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes.

Authors:  H Yamada; P J Martin; M A Bean; M P Braun; P G Beatty; K Sadamoto; J A Hansen
Journal:  Eur J Immunol       Date:  1985-12       Impact factor: 5.532

3.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  Induction, suppression and superinduction of lymphokine mRNA in T lymphocytes.

Authors:  J Shaw; K Meerovitch; J F Elliott; R C Bleackley; V Paetkau
Journal:  Mol Immunol       Date:  1987-05       Impact factor: 4.407

5.  Molecular cloning of cDNA encoding human interleukin-2 receptor.

Authors:  T Nikaido; A Shimizu; N Ishida; H Sabe; K Teshigawara; M Maeda; T Uchiyama; J Yodoi; T Honjo
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

6.  Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription.

Authors:  M Krönke; W J Leonard; J M Depper; S K Arya; F Wong-Staal; R C Gallo; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.

Authors:  C H June; J A Ledbetter; M M Gillespie; T Lindsten; C B Thompson
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

8.  Serological visualization of interleukin 2.

Authors:  G Steinmann; P Conlon; S Hefeneider; S Gillis
Journal:  Science       Date:  1983-06-10       Impact factor: 47.728

9.  Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells.

Authors:  S C Clark; S K Arya; F Wong-Staal; M Matsumoto-Kobayashi; R M Kay; R J Kaufman; E L Brown; C Shoemaker; T Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

  10 in total
  22 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives.

Authors:  M Schleuning; V Brumme; W Wilmanns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

Review 3.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 4.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Expression of cytolytic mediators by synovial fluid lymphocytes in rheumatoid arthritis.

Authors:  L H Young; S V Joag; P Y Lin; S F Luo; L M Zheng; C C Liu; J D Young
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 6.  Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma.

Authors:  Alexis L Santana; Diane Felsen; John A Carucci
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 7.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

8.  The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis.

Authors:  D M Chang; S F Chiao
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

9.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

Review 10.  Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.